异丙醇胺系列产品
Search documents
红宝丽:公司主营产品为环氧丙烷及其衍生品硬泡组合聚醚、异丙醇胺系列产品等
Zheng Quan Ri Bao Wang· 2025-11-20 13:13
证券日报网讯红宝丽(002165)11月20日在互动平台回答投资者提问时表示,公司主营产品为环氧丙烷 及其衍生品硬泡组合聚醚、异丙醇胺系列产品等。 ...
红宝丽:公司异丙醇胺系列产品目前设计总产能规模为9万吨
Zheng Quan Ri Bao· 2025-10-31 08:41
Core Viewpoint - Hongbaoli's isopropanolamine series products have a total designed production capacity of 90,000 tons, with applications across various industries including cleaning agents, oil and gas refining, and pharmaceuticals [2] Group 1: Company Overview - The company has expanded its isopropanolamine product applications through technological innovation [2] - The total designed production capacity for isopropanolamine is 90,000 tons [2] Group 2: Industry Applications - Isopropanolamine is widely used in synthetic surfactants, high-end electronic cleaning agents, industrial and household cleaning agents, desulfurizers in oil and gas refining, pharmaceutical intermediates, pesticide intermediates, and metal cutting [2] - The product also finds applications in coatings and new energy sectors [2]
红宝丽跌2.02%,成交额2.04亿元,主力资金净流出2699.20万元
Xin Lang Cai Jing· 2025-10-14 05:18
Core Viewpoint - Hongbaoli's stock price has experienced fluctuations, with a year-to-date increase of 105.90%, but a recent decline in the last 20 and 60 days, indicating potential volatility in investor sentiment [1][2]. Group 1: Stock Performance - On October 14, Hongbaoli's stock price fell by 2.02%, trading at 8.73 CNY per share, with a total market capitalization of 6.419 billion CNY [1]. - The stock has seen a trading volume of 204 million CNY, with a turnover rate of 3.18% [1]. - Year-to-date, the stock has risen by 105.90%, but has decreased by 13.56% over the last 20 days and 9.63% over the last 60 days [1]. Group 2: Capital Flow - There was a net outflow of 26.992 million CNY from main funds, with large orders showing a buy of 26.505 million CNY and a sell of 50.866 million CNY [1]. - The last appearance on the "Dragon and Tiger List" was on August 29, with a net buy of -283 million CNY on that day [1]. Group 3: Company Overview - Hongbaoli Group Co., Ltd. was established on June 23, 1994, and listed on September 13, 2007, focusing on epoxy propylene derivatives [2]. - The main business revenue composition includes 90.52% from epoxy derivatives, 9.40% from material trading, and 0.09% from insulation materials [2]. - As of June 30, the number of shareholders increased by 13.85% to 154,600, with an average of 4,706 circulating shares per person, a decrease of 12.17% [2]. Group 4: Financial Performance - For the first half of 2025, Hongbaoli reported a revenue of 1.245 billion CNY, a year-on-year decrease of 1.10%, and a net profit attributable to shareholders of 24.389 million CNY, down 35.51% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 564 million CNY in dividends, with 132 million CNY distributed in the last three years [2].
红宝丽跌2.00%,成交额3.42亿元,主力资金净流出266.21万元
Xin Lang Cai Jing· 2025-09-05 02:13
Core Viewpoint - Hongbaoli's stock price has shown significant volatility, with a year-to-date increase of 142.45%, but recent trading indicates a net outflow of funds, suggesting potential investor caution [1][2]. Company Overview - Hongbaoli Group Co., Ltd. is located in Nanjing, Jiangsu Province, established on June 23, 1994, and listed on September 13, 2007. The company specializes in epoxy propylene derivatives, including polyurethane rigid foam composite polyether and isopropanolamine series products, as well as the research, production, and sales of epoxy propylene, benzoyl peroxide, and polyurethane insulation boards [2]. - The main business revenue composition is as follows: epoxy propylene derivatives 90.52%, material trading and others 9.40%, and insulation materials 0.09% [2]. - Hongbaoli belongs to the Shenwan industry classification of basic chemicals - chemical products - polyurethane, and is associated with concepts such as margin trading, new materials, wind energy, QFII holdings, and the Belt and Road Initiative [2]. Financial Performance - As of June 30, the number of shareholders for Hongbaoli was 154,600, an increase of 13.85% from the previous period, with an average of 4,706 circulating shares per person, a decrease of 12.17% [2]. - For the first half of 2025, Hongbaoli reported operating revenue of 1.245 billion yuan, a year-on-year decrease of 1.10%, and a net profit attributable to shareholders of 24.39 million yuan, down 35.51% year-on-year [2]. - Since its A-share listing, Hongbaoli has distributed a total of 564 million yuan in dividends, with 132 million yuan distributed over the past three years [2].
晓数点丨4月十大牛股出炉:联合化学逾159%涨幅问鼎榜首
Di Yi Cai Jing· 2025-05-01 02:39
Core Viewpoint - The top-performing stocks in April include United Chemical and Guofang Group, with significant price increases of 159.09% and 117.10% respectively, amidst a general market decline [1][3]. Stock Performance Summary - **United Chemical**: Achieved a cumulative increase of 159.09% in April, with two trading days recording a 20% limit up. The company reported a revenue of 535 million yuan for 2024, a 24.80% increase year-on-year, and a net profit of 56.43 million yuan, up 66.81% [5]. - **Guofang Group**: Experienced a 117.10% increase, despite multiple risk warnings. The company reported a revenue of 757 million yuan for 2024, a 21.92% decrease, and a net profit of 58.01 million yuan, down 63.23% [6]. - **Hongbaoli**: Recorded a 104.27% increase, with eight trading days hitting the limit up. The company is undergoing technical modifications for its epoxy propylene project, which has not yet generated sales revenue [7]. - **ST Yushun**: Increased by 88.49%, with 16 trading days hitting the limit up. The company announced a significant asset restructuring involving a data center project [8]. - **Zhongqi New Materials**: Achieved an 85.72% increase, with a major share transfer that changed its controlling shareholder [9]. - **Lintai New Materials**: Increased by 84.94%, reporting a revenue of 101 million yuan for Q1 2025, a 107.43% increase, and a net profit of 38.36 million yuan, up 287.62% [10]. - **Wancheng Group**: Increased by 82.79%, reporting a revenue of 10.821 billion yuan for Q1 2025, a 124.02% increase, and a net profit of 215 million yuan, up 3344.13% [11][12]. - **Anji Food**: Increased by 76.69%, with a revenue of 607 million yuan for 2024, a 4.06% decrease, and a net profit of 38.33 million yuan, up 23.29% [13]. - **Leshan Electric Power**: Increased by 71.69%, with multiple risk warnings regarding high stock price increases [14]. - **Redick**: Increased by 70.20%, with ongoing uncertainty regarding its acquisition activities [15].
6天5板化工大牛股,一季度净利同比下降24%!多次澄清环氧丙烷项目未形成收入
2 1 Shi Ji Jing Ji Bao Dao· 2025-04-23 02:35
Group 1 - The chemical sector is experiencing speculation around propylene oxide, with the stock of Hongbaoli (002165.SZ) hitting the limit up for six days, recording a turnover rate of 44.1% [1] - Global chemical giants Covestro and LyondellBasell announced the permanent closure of their joint propylene oxide production facility, with an annual capacity of approximately 315,000 tons, leading to expectations of price increases due to supply shortages [1] - Hongbaoli reported a revenue of 654 million yuan for Q1 2025, a year-on-year increase of 9.48%, but a net profit of 22.0027 million yuan, a decrease of 23.68% due to lower product prices and rising raw material costs [1] Group 2 - For the full year 2024, Hongbaoli achieved a revenue of 2.726 billion yuan, a year-on-year increase of 2.98%, and a net profit of 584.954 million yuan, a year-on-year increase of 52.8% [1] - The company plans to distribute a cash dividend of 0.4 yuan per 10 shares (including tax) [1] - Hongbaoli's main business includes the research, production, and sales of propylene oxide derivatives, such as polyurethane rigid foam composite polyether and isopropanolamine series products [1] Group 3 - Hongbaoli clarified that its propylene oxide project is undergoing technical modifications and has not yet generated sales revenue, thus not impacting the company's performance [2] - The project is expected to enter trial production by the end of 2025 [2]